- Home
- EBMT vs XFOR Comparison
EBMT vs XFOR Comparison
Compare EBMT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBMT
- XFOR
- Stock Information
- Founded
- EBMT 1922
- XFOR 2014
- Country
- EBMT United States
- XFOR United States
- Employees
- EBMT N/A
- XFOR N/A
- Industry
- EBMT Major Banks
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBMT Finance
- XFOR Health Care
- Exchange
- EBMT Nasdaq
- XFOR Nasdaq
- Market Cap
- EBMT 133.9M
- XFOR 118.4M
- IPO Year
- EBMT N/A
- XFOR N/A
- Fundamental
- Price
- EBMT $17.53
- XFOR $3.34
- Analyst Decision
- EBMT
- XFOR Strong Buy
- Analyst Count
- EBMT 0
- XFOR 3
- Target Price
- EBMT N/A
- XFOR $72.33
- AVG Volume (30 Days)
- EBMT 48.2K
- XFOR 150.6K
- Earning Date
- EBMT 04-29-2025
- XFOR 05-01-2025
- Dividend Yield
- EBMT 3.23%
- XFOR N/A
- EPS Growth
- EBMT 26.99
- XFOR N/A
- EPS
- EBMT 1.41
- XFOR 2.16
- Revenue
- EBMT $82,271,000.00
- XFOR $31,364,000.00
- Revenue This Year
- EBMT N/A
- XFOR $355.69
- Revenue Next Year
- EBMT $6.33
- XFOR $140.28
- P/E Ratio
- EBMT $12.41
- XFOR $1.54
- Revenue Growth
- EBMT 0.06
- XFOR N/A
- 52 Week Low
- EBMT $12.42
- XFOR $3.05
- 52 Week High
- EBMT $18.37
- XFOR $34.20
- Technical
- Relative Strength Index (RSI)
- EBMT 56.47
- XFOR 22.00
- Support Level
- EBMT $17.46
- XFOR $3.14
- Resistance Level
- EBMT $18.49
- XFOR $3.41
- Average True Range (ATR)
- EBMT 0.37
- XFOR 0.60
- MACD
- EBMT 0.02
- XFOR 0.01
- Stochastic Oscillator
- EBMT 35.57
- XFOR 8.10
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.